Cocrystal pharma reports third quarter 2020 financial results and provides update on antiviral programs

– continued progress of covid-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3cl) underway and lead preclinical molecule selection expected by year end –

COCP Ratings Summary

COCP Quant Ranking